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We present a non-human primate mycobacterial growth inhibition assay (MGIA) using in vitro blood or cell co-culture with the aim
of refining and expediting early tuberculosis vaccine testing. We have taken steps to optimise the assay using cryopreserved
peripheral blood mononuclear cells, transfer it to end-user institutes, and assess technical and biological validity. Increasing cell
concentration or mycobacterial input and co-culturing in static 48-well plates compared with rotating tubes improved intra-assay
repeatability and sensitivity. Standardisation and harmonisation efforts resulted in high consistency agreements, with repeatability
and intermediate precision <10% coefficient of variation (CV) and inter-site reproducibility <20% CV; although some systematic
differences were observed. As proof-of-concept, we demonstrated ability to detect a BCG vaccine-induced improvement in growth
inhibition in macaque samples, and a correlation between MGIA outcome and measures of protection from in vivo disease
development following challenge with either intradermal BCG or aerosol/endobronchial Mycobacterium tuberculosis (M.tb) at a
group and individual animal level.
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INTRODUCTION
Tuberculosis (TB) is the leading cause of death due to an infectious
pathogen with an estimated 10 million new cases and 1.42 million
deaths in 20191. The only available vaccine, BCG, is insufficient and
a new vaccine is urgently needed. A major barrier to the
development of an efficacious vaccine is the lack of a validated
correlate of protection from TB, although several potential
biomarkers have been proposed2–4. As such, novel TB vaccine
candidates or regimens are currently evaluated using preclinical
models including non-human primates (NHPs). The use of NHPs in
medical research is emotive5, and assessment of protective TB
vaccine efficacy currently necessitates in vivo challenge with
virulent Mycobacterium tuberculosis (M.tb), a procedure resulting in
disease development and classified in macaques as ‘Moderate
Severity’ under UK ASPA licensure and European legislation6.
Sufficient animal numbers are required to ensure reliable
conclusions, and experiments are relatively time- and cost-
consuming requiring high biosafety containment facilities7.
Macaques are widely considered the most relevant model for
the evaluation of TB vaccine candidates, and are essential in
supporting advancement into clinical trials8. It is critical that new
tools are developed and exploited to facilitate vaccine testing in
macaques in line with the 3Rs principles of replacement, reduction
and refinement of the use of animals in scientific research9.
In the absence of a validated correlate or surrogate of protection
from TB, functional assays such as mycobacterial growth inhibition
assays (MGIAs) may offer a valuable complementary tool for vaccine
evaluation. The ‘sum-of-the-parts’ outcome of these in vitro/ex vivo
assays measures the contributions of multiple components of the
immune response and their interactions within their immune
environment. As such, they aim to give an unbiased measure of the
ability of whole blood or cell samples to control mycobacterial
growth without the limitation of having to pre-select individual
immune parameters of unclear relevance10. A successful, validated
MGIA could be used to down-select experimental TB vaccine
candidates at an early stage of development, reducing the number
progressing to virulent M.tb challenge experiments. Control of
different mycobacterial strains and isolates, and underlying immune
mechanisms, can be explored using cells from a single group of
vaccinated animals, further reducing animal numbers. Several
MGIAs have been reported using samples from humans11–16,
mice17–23 and cattle24–26, many demonstrating ability to detect a
BCG vaccine-induced improvement in growth inhibition. Further-
more, they have been applied to clinical cohorts of patients with
latent TB infection and active TB disease to study immune
mechanisms or correlates of mycobacterial control including
monocytes, memory B-cells and cytokine responses27,28.
To date, there are no reports of an MGIA for use in the macaque
model of TB vaccine development, although some of the authors
have recently applied the assay described here to detect a signal
after BCG vaccination and experimental M.tb infection in
macaques29,30. A macaque MGIA would be particularly valuable
not only from a 3Rs perspective, but also as an opportunity for
biological assay validation by correlating MGIA outcome with
direct measures of in vivo protection from M.tb challenge, which is
not possible in humans. The assay could then be bridged to use in
humans with increased confidence. In the absence of an effective
TB vaccine, BCG vaccination, which offers partial and quantifiable
protection against M.tb challenge in NHPs31–35, is a bench-mark
for assessing potential correlates or surrogates of protection. As
protection afforded by BCG vaccination in humans and NHPs is
variable36,37, we have considered the association between out-
comes of in vivo challenge and MGIA on a per-individual as well as
group basis. Alongside our efforts to optimise and biologically
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validate the NHP MGIA, we sought to transfer and harmonise a
standardised protocol between laboratories and assess reprodu-
cibility at multiple levels. Such activities are critical to ensure that
3Rs impact is maximised and comparable information can be
extracted from ongoing and future studies of different preclinical
vaccine candidates across organisations.
RESULTS
Mycobacterial growth in the direct whole blood MGIA is inhibited
following BCG vaccination and correlates with BCG recovered
from the lymph node following in vivo BCG challenge
Samples were taken from eight cynomolgus macaques from Study
1 that received BCG vaccination by the intradermal (ID) route.
Applying the whole blood MGIA, significantly improved control of
BCG growth was observed at 8 weeks and 20 weeks post-BCG
vaccination compared with baseline (p= 0.0048, mean difference
(MD)= 0.60 log10 CFU, 95% CI 0.23–0.97; and p= 0.0412, MD=
0.37 log10 CFU, 95% CI 0.02–0.72 respectively; RM one-way ANOVA
with Dunnett’s post-test, p= 0.0002, F(1.44, 10.06)= 27.2; Fig. 1a).
Using M.tb H37Rv as the MGIA inoculum, there was significantly
reduced M.tb growth at 4 weeks and 8 weeks post-BCG
vaccination compared with baseline (p= 0.040, MD= 0.12 log10
CFU, 95% CI 0.006–0.23; and p= 0.0006, MD= 0.39 log10 CFU, 95%
CI 0.22–0.56 respectively; RM one-way ANOVA with Dunnett’s
post-test, p < 0.0001, F(2.46, 17.18)= 27.40; Fig. 1b), but not at
20 weeks post-BCG vaccination. Using M.tb as the MGIA inoculum
resulted in superior repeatability between replicate cultures
compared with BCG (median CV= 2.3% and 3.9% respectively;
p= 0.02, two-tailed Wilcoxon test; Supplementary Fig. 1a); the
intra-class correlation coefficient (ICC) for M.tb was 0.69 (‘sub-
stantial agreement’) and for BCG was 0.56 (‘moderate agreement’).
However, the MGIA vaccine response (post-vaccination growth –
baseline growth) was greater at 8 weeks and 20 weeks post-
vaccination using BCG compared with M.tb, although this was not
statistically significant (Supplementary Fig. 1b).
All animals were challenged ID with high-dose BCG (as a
potential surrogate for virulent M.tb) at 21 weeks post-BCG
vaccination, and 2 weeks later a challenge site biopsy and axillary
lymph nodes (LN) were taken and BCG quantified by solid agar
culture and qPCR. As previously reported, there was no difference
in biopsy CFU recovery between the naïve and BCG-vaccinated
groups38, and we did not see an association between this measure
and the MGIA response. However, there was a significant
reduction in LN CFU recovery from the BCG-vaccinated group
compared with the naïve group following BCG challenge38, and
we observed a significant correlation between LN CFU and M.tb
growth in the MGIA at peak of response (8 weeks post-
vaccination) on a per-animal basis (p= 0.04, r= 0.75, Spearman’s,
Fig. 1c). Furthermore, there was a significant association between
LN CFU and M.tb MGIA vaccine response (post-vaccination growth
– baseline growth) at 8 weeks post-BCG vaccination (p= 0.001,
r= 0.95, Spearman’s, Fig. 1d). These associations were not
Fig. 1 Mycobacterial growth inhibition in the direct whole blood MGIA is enhanced following BCG vaccination and correlates with BCG
recovered from the lymph node following in vivo BCG challenge. Samples were collected from eight cynomolgus macaques from Study 1
that received BCG vaccination by the ID route. The MGIA was performed using whole blood collected at baseline, 4 weeks, 8 weeks and
20 weeks post-BCG vaccination using (a) BCG Pasteur or (b) M.tb H37Rv as the inoculum. At 20 weeks after vaccination, all animals were
challenged by exposure to ID BCG, and CFU recovered from the lymph node was quantified 2 weeks later. Spearman’s rank correlations are
shown between lymph node CFU and (c) M.tb growth at 8 weeks post-BCG vaccination or (d) M.tb MGIA vaccine response (post-vaccination
growth–baseline growth) at 8 weeks post-BCG vaccination relative to baseline. Points represent individual animals with the mean of two
co-culture replicates. Normalised mycobacterial growth is equal to (log10 CFU of sample – log10 CFU of inoculum control). Boxes indicate the
median value with the interquartile range and whiskers indicate the minimum and maximum values. A repeated-measures one-way ANOVA
with Dunnett’s multiple comparisons test was performed (a, b) where *p-value < 0.05, **p-value < 0.01, and ***p-value < 0.001.
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statistically significant using the BCG MGIA, although there was a
correlation between BCG and M.tb growth in the two assays
(p= 0.0001, r= 0.63, Spearman’s, data not shown).
Optimisation of the NHP direct PBMC MGIA: increasing cell
number and co-culturing in static 48-well plates improves intra-
assay repeatability and assay sensitivity
Due to emerging concerns regarding haemoglobin levels
confounding the whole blood MGIA in small animal models29,
batch effects associated with performing the assay in real-
time39,40, and to maximise cryopreserved sample use from
historical studies to reduce the number of animals used41, we
sought to develop a cryopreserved PBMC-based MGIA for use with
macaque samples. Samples were taken from 12 Rhesus macaques
enrolled into Study 2; six unvaccinated controls, and six of which
received BCG vaccination by the ID route38. The MGIA was
performed using PBMC from baseline and 8 weeks post-BCG
vaccination according to the previously described ‘in-tube
protocol’ co-culturing 1 × 106 cells with 10% pooled human serum
and BCG in 2ml screw-cap 360° rotating tubes39.
Using a standard inoculum of 500 CFU BCG, a vaccine-induced
improvement in growth inhibition was not detected (Fig. 2a).
When the mycobacterial input was reduced to 50 CFU, intra-assay
variability between replicate cultures increased (median CV for
500 and 50 CFU= 2.59 and 6.14% respectively) and again an
effect of vaccination on mycobacterial growth was not detected
(data not shown). We therefore reduced the multiplicity of
infection (MOI) by increasing cell number rather than reducing
inoculum, co-culturing 5 × 106 cells with 500 CFU BCG in
singlicate. Under these conditions, a modest reduction in MGIA
growth was observed following BCG vaccination (p= 0.026, t(4)=
3.44, MD=−0.29 log10 CFU, 95% CI −0.52 to −0.06, paired t-test;
one-way ANOVA with Sidak’s post-test, p= 0.038, F(3, 18)= 3.47;
Fig. 2b). At 21 weeks, all Study 2 animals were challenged ID with a
standard dose of BCG, and 2 weeks later a challenge site biopsy
was taken and BCG quantified by culture on solid agar and qPCR.
Axillary LNs were not collected in this study. As previously
reported, the amount of BCG recovered from each biopsy was
very low, and a difference in BCG recovery between the naïve and
BCG-vaccinated groups was not detected38. We did not see an
association between biopsy CFU and MGIA response using either
assay protocol (data not shown).
It has recently been reported that co-culture of cells and
mycobacteria in static tissue culture plates with CO2 improves cell
viability and reproducibility in mouse splenocyte and human
PBMC direct MGIAs42,43. We therefore compared the in-tube
protocol with co-culture in 48-well plates using 1 × 106 or 3 × 106
cells collected from rhesus macaques from Study 3. Intra-assay
repeatability between replicates, as measured by CV, did not differ
between 1 × 106 and 3 × 106 cells for either condition, although
repeatability was improved using plates compared with tubes,
which was significant for the 1 × 106 cells condition (p= 0.007,
MD= 2.86%, 95% CI 0.62–5.10; one-way ANOVA with Tukey’s
post-test, p= 0.0038, F(3, 73)= 4.87; Supplementary Fig. 2a). The
ICC showed ‘slight to fair agreement’ between replicates using the
in-tube protocol (ICC= 0.493 and 0.301 for 1 × 106 and 3 × 106
cells respectively); but ‘substantial agreement’ between replicates
using the 48-well plate protocol (ICC= 0.795 and 0.605 for 1 × 106
and 3 × 106 cells respectively).
Due to limited cell availability, paired samples from Study 3 were
randomised to either the in-tube protocol with 1 × 106 and 3 × 106
cells (n= 6 naïve and n= 6 BCG vaccinated animals), or in a separate
experiment, the 48-well plate protocol with 1 × 106 and 3 × 106 cells
(n= 3 naïve and n= 9 BCG vaccinated animals). The randomised
groups showed similar levels of in vivo protection by all primary
outcomes (data not shown). A vaccine-induced improvement in
growth inhibition was not detected using the in-tube protocol for
either cell input (Fig. 3a, b). However, applying the 48-well plate
protocol, there was a trend towards improved mycobacterial growth
inhibition following BCG vaccination using 1 × 106 cells (Fig. 3c) and
a significant improvement using 3 × 106 cells (p= 0.018, t(6)= 3.24,
MD=−0.25 log10 CFU, 95% CI −0.43 to −0.06, paired t-test; p=
0.029, MD= 0.22 log10 CFU, 95% 0.02–0.41, one-way ANOVA with
Sidak’s post-test, p= 0.086, F(3, 18)= 2.58; Fig. 3d). The MGIA
vaccine response (post-vaccination growth – baseline growth) was
greater using 3 × 106 compared with 1 × 106 cells (p= 0.013, t(7)=
3.30, MD=−0.20 log10 CFU, 95% CI −0.34 to −0.06, paired t-test;
Supplementary Fig. 2b), and there was a significant correlation
between MGIA outcome for the two conditions (p= 0.02, r= 0.50,
Spearman’s; Supplementary Fig. 2c).
All animals in Study 3 were challenged in vivo with M.tb Erdman
by endobronchial installation at 38 weeks post-BCG vaccination.
The clinical parameters measured at necropsy were time to
humane endpoint (if fixed endpoint not reached), total pathology,
lung pathology, extra-thoracic pathology, lung CFU, C-reactive
protein (CRP) and weight change. Absolute growth in the MGIA at
week 8 was not associated with any of the measures of protection,
but MGIA vaccine response (post-vaccination growth – baseline
Fig. 2 Optimisation of the NHP direct PBMC MGIA. Samples were collected from 12 Rhesus macaques from Study 2, six of which were naïve
unvaccinated controls (green boxes), and six of which received BCG vaccination by the intradermal (ID) route (blue boxes). The MGIA was
performed using PBMC from baseline (circles) and 8 weeks post-BCG vaccination (triangles) according to the original ‘in-tube protocol’ co-
culturing in 2 ml screw-cap rotating tubes with (a) 1 × 106 PBMC or (b) 5 × 106 PBMC and a BCG inoculum of 500 CFU. Points represent
individual animals with the mean of two co-culture replicates (a) or a single co-culture (b). Normalised mycobacterial growth is equal to (log10
CFU of sample – log10 CFU of inoculum control). Boxes indicate the median value with the interquartile range and whiskers indicate the
minimum and maximum values. A one-way ANOVA with Sidak’s multiple comparisons test was performed where *p-value < 0.05.
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growth) using 1 × 106 cells correlated with total pathology, lung
pathology, extra-thoracic pathology and CRP on a per-animal basis
(p= 0.0003, r= 0.98; p= 0.0006, r= 0.96; p= 0.001, r= 0.95; and
p= 0.048, r= 0.71 respectively, Spearman’s, Fig. 3e–h).
Standardisation and harmonisation of the NHP direct PBMC MGIA
results in consistency agreement across replicates, assay runs and
sites
Based on the findings of our optimisation experiments, the
limitations of cell availability, and to ensure consistency with the
equivalent human assay43, the conditions of 3 × 106 cells co-
cultured in 48-well plates with 500 CFU BCG were selected for
future experiments. Side-by-side operator training was conducted
to transfer the optimised protocol from the developer institute
(henceforth referred to as site 1) to two additional end-user
institutes (sites 2 and 3).
PBMC samples collected from macaques enrolled into studies
described in this paper were assayed in duplicate to assess intra-
assay repeatability at the three different sites. The median CV
between replicate co-cultures was 2.69% (range 0.59–6.12%,
n= 8), 1.67% (range 0.78–8.52%, n= 5) and 2.71% (range
0–7.33%, n= 5) at sites 1, 2 and 3 respectively. The ICC values
were 0.90 (‘almost perfect’ agreement), 0.34 (‘fair’ agreement) and
0.95 (‘almost perfect’ agreement) respectively (Table 1).
A single sample set (n= 8) was assayed on two separate
occasions at site 1 to assess inter-assay precision (Fig. 4a). The
median CV between assay runs was 6.83% (range 2.13 to 7.76%)
with an ICC value of 0.80 (‘substantial’ agreement). While there
was a strong consistency agreement, mycobacterial growth was
systematically higher (shorter TTP) in run 2. As shown by Bland-
Altman analysis relating the difference between paired measure-
ments to the mean of the pair, this bias was not fully compensated
by normalising growth using the direct-to-MGIT inoculum controls
(mean bias= 0.39 log10 CFU, Fig. 4b). However, the difference
between the highest and lowest responses was consistent
between runs (0.66 and 0.64 log10 CFU respectively), and all
samples were within 95% limits of agreement (the interval of
1.96 standard deviations of the measurement differences either
side of the mean difference), which extended from 0.12 (95% CI,
−0.19 to 0.21) to 0.66 (95% CI, 0.58–0.97) log10 CFU.
Finally, inter-site comparisons were conducted between sites 1
and 2 (Fig. 4c) and sites 1 and 3 (Fig. 4e) using a shared BCG
Pasteur Aeras stock and two different shared sample sets (n= 8).
Between sites 1 and 2, the median CV was 14.19% (range
11.57–17.29%) with an ICC value of 0.57 (‘moderate’ agreement;
Table 2). Mycobacterial growth was consistently higher at site 1
compared with site 2; again this systematic difference was not
fully compensated by normalising against the direct-to-MGIT
inoculum controls, as shown by the Bland-Altman plot (mean
bias=−0.41 log10 CFU, Fig. 4d). However, the difference between
the highest and lowest responses was consistent between runs
(0.26 and 0.33 log10 CFU respectively), and all samples were within
the 95% limits of agreement, which extended from −0.61 (95% CI,
−0.89 to −0.54) to −0.21 (95% CI, −0.27 to 0.07) log10 CFU.
Between sites 1 and 3, the median CV was 3.17% (range
0.39–8.62%) with an ICC of 0.83 (‘almost perfect’ agreement;
Fig. 3 Optimisation of the NHP direct PBMC MGIA. Samples were collected from 24 Rhesus macaques from Study 3, nine of which were
naïve unvaccinated controls (green boxes), and 15 of which received BCG vaccination by the intradermal (ID) route (blue boxes). The MGIA
was performed using PBMC from baseline (circles) and 8 weeks post-BCG vaccination (triangles) according to the original ‘in-tube protocol’
co-culturing in 2ml screw-cap rotating tubes (a, b) or in static 48-well tissue culture plates (c, d). Co-cultures contained either 1 × 106 PBMC
(a, c) or 3 × 106 PBMC (b, d). Points represent individual animals with the mean of two co-culture replicates. Normalised mycobacterial growth
is equal to (log10 CFU of sample – log10 CFU of inoculum control). Boxes indicate the median value with the interquartile range and whiskers
indicate the minimum and maximum values. A one-way ANOVA was performed with Sidak’s multiple comparisons test where *p-value < 0.05.
At 38 weeks after BCG vaccination, all animals were challenged by endobronchial installation of M.tb and measures of pathology were
determined 2 weeks later. Correlations are shown between the MGIA vaccine response (post-vaccination growth – baseline growth) and
(e) total pathology, (f) lung pathology, (g) extra-thoracic pathology and (h) CRP using Spearman’s rank correlation coefficient.
Table 1. NHP MGIA intra-assay repeatability.
Site 1 (n= 11) Site 2 (n= 4) Site 3 (n= 13)
CV (%) 2.69 1.67 2.71
ICC 0.90 0.34 0.95
The median CV and ICC between replicate co-cultures was measured at
sites 1, 2 and 3.
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Table 2). There was a small mean bias of 0.11 log10 CFU between
sites 1 and 3 following normalisation but this was not significant;
the Bland-Altman 95% limits of agreement extended from −0.26
(95% CI, −0.70 to −0.15) to 0.49 (95% CI, 0.37–0.93) log10 CFU and
again all samples fell within this range (Fig. 4f).
Mycobacterial growth inhibition in the direct PBMC MGIA is
enhanced following alternative routes of BCG administration and
correlates with measures of protection from in vivo M.tb challenge
at an individual animal level
Samples were taken from 24 Rhesus macaques enrolled into Study
4. Six animals were unvaccinated controls, six received BCG
vaccination by the intradermal (ID) route, six received BCG
vaccination by the ID followed by intratracheal (IT) routes,
and six received BCG vaccination by the intravenous (IV) route35.
The optimised, standardised direct PBMC MGIA protocol was
applied to samples taken at baseline, week 8 and week 20 (the
closest time-point to day-of-challenge). Differences in MGIA
control of BCG growth were not observed in the naïve or BCG
ID groups over time, although there was a trend towards reduced
growth at 8 weeks following ID BCG vaccination (Fig. 5a, b).
However, there was a significant reduction in BCG growth at
20 weeks post-ID+ IT BCG vaccination (p= 0.015, MD= 0.33 log10
CFU, 95% CI 0.07–0.59, one-way ANOVA with Dunnett’s post-test,
p= 0.022, F(2, 13)= 5.18; Fig. 5c) and at 20 weeks post-IV BCG
vaccination (p= 0.0007, MD= 0.48 log10 CFU, 95% CI 0.25–0.71;
one-way ANOVA with Dunnett’s post-test, p= 0.001, F(2, 10)=
14.42; Fig. 5d) compared to baseline. There was also a reduction at
8 weeks following IV BCG vaccination (p= 0.04, t(3)= 3.60, MD=
−0.18 log10 CFU, 95% CI −0.34 to −0.02, paired t-test), but this
was no longer significant following correction for multiple
comparisons.
All animals were challenged by exposure to aerosol M.tb at
21 weeks after primary vaccination. Clinical parameters measured
at necropsy were time of disease control, lung pathology, total
pathology, lung lesion count, lesion:lung ratio, % weight loss, ESR,
and X-ray score. As previously reported, disease pathology was
reduced, and disease control improved, by all BCG vaccination
strategies compared with naïve animals. IV vaccination induced
Fig. 4 Standardisation and harmonisation of the NHP direct PBMC MGIA. The MGIA (3 × 106 cells, 500 CFU BCG in static 48-well plates) was
performed using PBMC collected from various studies described in this paper. A single sample set (n= 8) was assayed on two separate
occasions at site 1 to assess inter-assay precision (a, b). Inter-site comparisons were conducted between sites 1 (blue) and 2 (green) (c, d) and
between sites 1 (blue) and 3 (red) (e, f) using different shared sample sets (n= 8). Cultures were performed in duplicate or triplicate where cell
availability allowed; data are expressed as median values with interquartile range (a, c, e). TTP= BACTEC MGIT time to positivity. b, d, f show
Bland-Altman plots where the solid green line indicates the mean difference between measurements and the dotted red line indicates the
upper and lower limits of agreement (mean difference ±1.96 standard deviation of the difference) with red vertical bars showing the 95%
confidence intervals for the limits of agreement. Normalised mycobacterial growth is equal to (log10 CFU of sample – log10 CFU of inoculum
control).
Table 2. NHP MGIA inter-site reproducibility.
Site 1 vs. Site 2 (n= 8) Site 1 vs. Site 3 (n= 8)
CV (%) 14.19 3.17
ICC 0.57 0.83
The median CV and ICC is shown for shared sample sets assayed at
different laboratory sites.
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protection which surpassed that achieved by all other routes35.
Total pathology score at necropsy was lower in all BCG vaccinated
groups compared with naïve animals, which remained significant
in the IV BCG vaccinated group following correction for multiple
comparisons (p= 0.004, MD= 26.33 AU, 95% CI 7.76-44.9; one-
way ANOVA with Tukey’s post-test, p= 0.0065, F(3, 20)= 5.48; Fig.
5e). BCG growth in the MGIA at 20 weeks was significantly lower in
the ID+ IT and IV BCG vaccinated groups compared with the
naïve group using an unpaired t-test (p= 0.003, t(10)= 3.81,
MD=−0.23 log10 CFU, 95% −0.37 to −0.10; and p= 0.013, t(9)=
3.07, MD=−0.25 log10 CFU, 95% CI −0.44 to −0.07 respectively),
which remained significant in the IV vaccinated group following
correction for multiple comparisons (p= 0.047, MD= 0.25 log10
CFU, 95% CI 0.002–0.51, one-way ANOVA with Tukey’s post-test,
p= 0.034, F(3, 19)= 3.54; Fig. 5f).
MGIA vaccine response (post-vaccination growth – baseline
growth) at the peak of the MGIA response (week 20) was
significantly greater in the ID+ IT and IV BCG vaccinated groups
compared with the naïve group using an unpaired t-test (p=
0.0005, t(10)= 5.03, MD=−0.31 Δ log10 CFU, 95% CI −0.45 to
−0.17; and p= 0.005, t(7)= 4.00, MD=−0.51 Δ log10 CFU, 95% CI
−0.81 to −0.21 respectively), but this was not significant following
correction for multiple comparisons (Fig. 5g). There was no
association between MGIA outcome following BCG vaccination
and any of the measures of in vivo protection on a per-individual
basis when considering all animals. However, for some animals
disease reached humane endpoint criteria necessitating euthana-
sia prior to the end of the study; when these animals were
excluded from the analysis (ID BCG n= 3, ID+ IT BCG n= 2 and IV
BCG n= 1), there was a weak but significant association between
MGIA vaccine response (post-vaccination growth – baseline
growth) at the peak of response (20 weeks) following BCG
vaccination and total pathology, lung lesion count and ESR
(p= 0.02, r= 0.71; p= 0.02, r= 0.72; and p= 0.03, r= 0.71
respectively, Spearman’s, Fig. 5h–j).
DISCUSSION
We aimed to adapt the direct MGIA, previously described in humans
and mice20,21,39,42,43, as a surrogate read-out of vaccine-induced
Fig. 5 Mycobacterial growth inhibition is enhanced following alternative routes of BCG administration. Samples were collected from 24
Rhesus macaques from Study 4. Six animals were unvaccinated (green boxes), six received BCG vaccination by the intradermal (ID) route (blue
boxes), six received BCG vaccination by the ID followed by intratracheal (IT) routes (orange boxes), and six received BCG vaccination by the
intravenous (IV) route (red boxes). The MGIA (3 × 106 cells, 500 CFU BCG in static 48-well plates) was performed using PBMC and autologous
serum collected at baseline (circles), and at 8 weeks (triangles) and 20 weeks (diamonds) post-BCG vaccination in the (a) naïve, (b) ID BCG, (c)
ID+ IT BCG and (d) IV BCG vaccinated groups. At 21 weeks after primary vaccination, all animals were challenged by exposure to aerosol M.tb
and total pathology was determined 2 weeks later (e). BCG growth in the MGIA (f) and MGIA vaccine response (post-vaccination growth –
baseline growth) (g) at 20 weeks post-vaccination were compared between groups. Correlations are shown between the MGIA vaccine
response (post-vaccination growth – baseline growth) at 20 weeks and (h) total pathology, (i) lung lesion count and (j) ESR using Spearman’s
rank correlation coefficient. Points represent individual animals. Normalised mycobacterial growth is equal to (log10 CFU of sample – log10 CFU
of inoculum control). Boxes indicate the median value with the interquartile range and whiskers indicate minimum and maximum values. A
one-way ANOVA was performed with Dunnett’s multiple comparisons test (a–d) or Tukey’s multiple comparisons test (e–g) where *p-value <
0.05, **p-value < 0.01 and ***p-value < 0.001.
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protection against TB in the macaque model. The enhanced control
of mycobacterial growth observed in the direct whole blood MGIA
following BCG vaccination in cynomolgus macaques is consistent
with in vivo data demonstrating a partially protective effect of BCG
vaccination in this species44,45, and with our previous observations
in rhesus macaques29 and humans39. Notably, the peak of the
human MGIA response was reported at 8 weeks post-BCG
vaccination with a reduced effect by 24 weeks; a kinetic mirrored
in our study39. This may be related to immunogenicity following ID
BCG vaccination, with a peak PPD-specific IFN-γ T-cell response at
4–8 weeks which wanes by 20–24 weeks39,46. A similar MGIA kinetic
and correlation was observed for BCG or M.tb inocula, supporting
the use of BCG as a surrogate in line with previous work28,40. While
clumping issues with our initial BCG Pasteur stock and lower growth
may have reduced intra-assay reproducibility compared with M.tb,
the MGIA vaccine response (post-vaccination growth – baseline
growth) was greater using BCG. On balance we pursued assay
development using a standardised, homogeneous BCG Pasteur
stock to maximise logistical feasibility and transferability. One
advantage of the direct MGIA is that manipulations (eg. reporter
genes) are not required to evaluate different mycobacterial strains
and isolates, but it should be noted that the optimal MOI may be
strain-specific.
The finding that intra-assay repeatability and sensitivity to
detect vaccine-induced control of mycobacterial growth in the
PBMC MGIA is improved by increasing cell concentration or
mycobacterial input is consistent with human and mouse direct
MGIA work21,43, and illustrates the critical importance of MOI
optimisation. We further improved these parameters by co-
culturing in 48-well plates rather than rotating 2ml tubes, again
in line with findings using human and mouse cells42,43, and likely
due to CO2 availability and lack of mechanical perturbation. Cell
number is limiting in macaque studies due to permitted blood
collection volumes; we therefore recommend a rational compro-
mise of 3 million cells per co-culture. Mean cell viability at the end
of the co-culture period under these conditions (72%) is
comparable to that reported for the human direct PBMC MGIA
(73%)43. One limitation of these early studies was the use of
pooled human serum; for the final study (and going forward)
autologous timepoint-matched macaque serum was included to
capture serum component (eg. antibody) influences. An additional
potential limitation is the relatively older age of the animals in
Studies 1 and 2, which may be associated with a weaker immune
response to vaccination47, however we did observe in vivo
protection following mycobacterial challenge in BCG-vaccinated
older animals as reflected in the MGIA.
Following side-by-side training with end-users by a ‘lead
operator’ as recommended by Smith et al.48, repeatability and
intermediate precision of the optimised assay were consistently
<10% CV, and inter-site reproducibility <20% CV. Some lower
reproducibility outcomes were likely influenced by the homo-
geneous sample set used49; indeed for the comparison between
sites 1 and 3, agreement was higher using samples with a broader
dynamic range (between-sample standard deviation= 0.34 com-
pared with 0.08 for the comparison between sites 1 and 2). Based
on consistency agreements, our reproducibility values are
comparable to the human direct PBMC MGIA43 and well within
the 50% limit of acceptable variation suggested for the measure-
ment of a bacterial target in a cell-based assay50. This affords
confidence in assay transferability to maximise both scientific and
3Rs impact. However, we did observe some systematic differences,
likely driven by variation in mycobacterial inoculum input (a
difference of 0.2 log10 CFU and 0.5 log10 CFU between assay runs
at site 1 and in the site 1–2 comparison respectively), despite
exchanging a common BCG stock and normalising growth values
against direct-to-MGIT inoculum controls. Importantly the delta
between the highest and lowest values, which may be the most
relevant measure, was consistent. Nonetheless, we recommend
batching samples for direct comparisons, and further work should
aim to standardise the mycobacterial inoculum and define an
internal reference standard.
Sharpe et al.35 reported that IV BCG-induced protection against
aerosol M.tb challenge surpassed that achieved by all other routes
tested. Using samples from this study we replicated this finding
using the direct PBMC MGIA, although sensitivity was lower than
in vivo challenge. This is perhaps unsurprising, given the MGIA
attempts to model a complex and dynamic biological system
using cells present at a specific moment in time. Interestingly
while growth inhibition in the ID BCG group was waning by week
20, consistent with Study 1 MGIA data presented here and with
previous MGIA findings in humans39, this was not the case in the
ID+ IT and IV BCG groups, suggesting that protection afforded by
these routes may be more durable. Indeed, immunogenicity
measures remained higher for longer in the ID+ IT and IV BCG
groups and were significantly greater at day-of-challenge than in
the ID BCG group35. This is also consistent with recent work
demonstrating high levels of protection at 24 weeks post-IV (but
not -ID) BCG vaccination in rhesus macaques51. Both studies
observed higher specific T-cell responses in the periphery
following IV BCG vaccination, which may drive the superior MGIA
control observed35,51. However, Darrah et al. also noted a high
frequency of antigen-responsive T-cells in the bronchoalveolar
lavage, supporting the need for a complementary lung-based
direct MGIA as recently described in the murine model22.
An NHP MGIA offers the unique opportunity for biological
validation at a per-individual as well as per-group level. In Study 1,
there was a significant correlation between post-challenge LN CFU
recovery and M.tb growth in the whole blood MGIA at the peak
response, and moreso the MGIA vaccine response (post-vaccina-
tion growth – baseline growth). While there was no correlation
between MGIA outcome and biopsy CFU recovery, the value of
this measure in macaques is unclear due to local tissue structure;
BCG could not be detected in 5/7 naïve animals and biopsy CFU
did not differ between naïve and BCG-vaccinated animals
following high-dose BCG challenge38. These limitations may also
account for the lack of correlation between individual challenge
outcome and MGIA in Study 2, where biopsy CFU was the only
in vivo read-out. In addition to Study 1, MGIA vaccine response
(post-vaccination growth–baseline growth) correlated with multi-
ple post M.tb-challenge protection measures in Study 3 and, to a
lesser extent, Study 4. Taken together, this suggests that post-
vaccination control of growth relative to baseline is a better
surrogate of in vivo protection than absolute inhibition at a given
time-point. One limitation of these M.tb challenge studies is that
pulmonary M.tb burden was not measured in Study 4, and did not
correlate with MGIA outcome in Study 3, although this endpoint
has not been standardised8.
A degree of biological validation was achieved using both
cynomolgus and rhesus macaques of different genetic back-
grounds. While rhesus macaques are typically more susceptible to
M.tb infection and disease than cynomolgus, the Mauritian
cynomolgus genotype used here more closely resembles the
susceptibility profile of rhesus8,30. BCG vaccine efficacy has also
been shown to be superior in cynomolgus compared with rhesus
macaques52, and indeed we observed strongly enhanced MGIA
control post-BCG vaccination in this species. The direct NHP MGIA
is now being implemented for further evaluation at the end-user
institutes, where improved mycobacterial growth inhibition has
been demonstrated following M.tb infection30, consistent with
studies in recently M.tb-infected humans27,28. Additional work
should aim to further improve assay sensitivity, evaluate
performance in trials of novel TB vaccine candidates and
interrogate immune mechanisms of control. In the human direct
MGIA, mycobacterial growth inhibition has been variously
associated with ratio of monocytes to lymphocytes27,28,53, poly-
functional CD4 + T-cells54, B-cell and IgG1 responses28, cytokines
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associated with trained immunity27 and distinct transcriptomic
profiles55; similar mechanisms may contribute in the macaque56.
In conclusion, we have indicated predictive utility of the NHP
MGIA across different macaque species and challenge contexts.
Our findings support the potential of the direct NHP MGIA as a
promising tool to facilitate the early testing of novel TB vaccine
candidates and reduce those progressing to virulent M.tb
challenge studies. Application of the assay to assess control of
different mycobacterial strains and isolates, and immune mechan-
isms involved, would further reduce the number of in vivo
challenge experiments in macaques. Importantly, biologically
validating the MGIA as a reliable surrogate of vaccine-induced
protection (against direct in vivo measures such as lung pathology
and/or bacterial burden) in the NHP model, would then allow it to




To minimise the number of animals used in line with the 3Rs principles,
samples were taken from ongoing or historical vaccination studies for
which sample sizes were calculated based on power to observe a
difference between groups in protection from in vivo challenge. The
animals from which samples were used in MGIA studies were cynomolgus
macaques of Mauritian genotype (Study 1, n= 8), rhesus macaques of
Indian genotype (Study 2, n= 12 and Study 4, n= 24) or rhesus macaques
of Chinese genotype (Study 3, n= 24). In all cases, animals were captive-
bred for research purposes, and a single animal was considered an
experimental unit; samples collected from a total of 67 animals were used.
The PBMC and serum samples used for MGIA analysis were not selected
but were provided according to availability, and were unblinded with
individual animal identifiers provided. The samples represent a spectrum
of more or less protected phenotypes for correlative investigation against
possible MGIA signals. Laboratory staff were blinded as to levels of in vivo
protection when samples were tested in the MGIA. A summary of the
samples used for MGIA assays, the studies from which they originated,
animal characteristics and treatment group comparisons is provided in
Table 3.
The following samples do not have MGIA data because either PBMC
and/or timepoint-matched autologous serum were unavailable, because
an insufficient number of viable cells were recovered post-thawing, or
occasionally because MGIA cultures were contaminated (TTP < 48 h): one
animal in the BCG vaccinated group from Study 2 for the MGIA with 5 ×
106 cells with 500 CFU BCG (Fig. 2b); one animal in the Study 3 naïve group
at 8 weeks for the 3 × 106 cells in-tube assay (Fig. 3b), one animal in the
BCG vaccinated group at baseline for both in-plate assays (Fig. 3c, d) and
one animal in the BCG vaccination group at 8 weeks for the 3 × 106 cells in-
plate assay (Fig. 3d); two animals in the Study 4 ID+ IT group at week 8
(Fig. 5c), two animals from the IV group at weeks 0 and 8 and 1 animal
from the IV group at week 20 (Fig. 5d); one animal from the site 1 and 2
comparison at site 1 (Fig. 4c).
For the original in vivo studies, animals were obtained from established
breeding colonies at Public Health England in the UK (Studies 1, 2 and 4),
or purchased by the Biomedical Primate Research Centre in 2008 from a
certified provider in the Netherlands (Study 3). None of the animals had
been used previously for experimental procedures. Animals were socially
housed throughout the experiments and provided with enrichment in the
form of food and non-food items on a daily basis; animal welfare was
monitored daily. In all studies, absence of previous exposure to
mycobacterial antigens was confirmed by a tuberculin skin test applied
as part of colony management practice and/or by screening using an
ex vivo IFN-γ ELISpot upon mycobacterial recall stimulation of PBMC with
purified protein derivative (PPD) of M.tb (Mabtech, Sweden; U-Cy Tech,
Utrecht). Animals were sedated by intramuscular (IM) injection of ketamine
hydrochloride (Ketaset, 100mg/ml, Fort Dodge Animal Health Ltd,
Southampton, UK; 10 mg/kg) for procedures requiring removal from their
housing.
The macaque studies included in this paper complied with all relevant
ethical regulations for animal testing and research. For Studies 1, 2 and 4,
study design and procedures were approved by the Public Health England
Porton Down Animal Welfare and Ethical Review Committee and
authorized under an appropriate UK Home Office project license. Animals
were housed in compatible social groups in accordance with the Home
Office (UK) Code of Practice for the Housing and Care of Animals Used in
Scientific Procedures (1989) and the National Centre for Refinement,
Reduction and Replacement (NC3Rs) Guidelines on Primate Accommoda-
tion, Care and Use, August 2006 (NC3Rs, 2006). For Study 3, ethical
approval was obtained from the independent animal ethics committee
(Dierexperimentencommissie, DEC, Netherlands; dossier number 579).
Housing and animal care procedures were in compliance with Dutch law
on animal experiments, European directive 86/609/EEC, and the ‘Standard
for Humane Care and Use of Laboratory Animals by Foreign Institutions’
provided by the Department of Health and Human Services of the United
States National Institutes of Health (NIH, identification number A5539-01).
The BPRC is accredited by the American Association for Accreditation of
Laboratory Animal Care since 2012.
In Studies 1, 2 and 4, treatment groups were randomly assigned to
socially compatible cohorts (single gender, behaviourally harmonious
groups) using software-generated random number allocations (Microsoft
Excel). In Study 3, animals were stratified into groups on the basis of age,
body weight and indicators for social housing; specific treatment was
assigned to groups randomly with treatment groups randomly housed
across animal rooms throughout classified experimental facilities at BPRC.
In Studies 1, 2 and 3, n= 8, n= 6 and n= 15 animals respectively
received an adult human dose of BCG Danish strain 1331 (SSI,
Copenhagen) 2–8 × 105 CFU intradermally (ID) into the upper arm under
sedation. The BCG vaccine was prepared and administered according to
the manufacturer’s instructions for preparation of vaccine for administra-
tion to human adults, by addition of 1 ml Sauton’s diluent to a lyophilised
vial. In Study 4, animals were randomised to be unvaccinated controls
Table 3. Summary of samples used in MGIA studies.
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(n= 6), to receive 2–8 × 105 CFU BCG ID (n= 6), to receive 2–8 × 106 CFU
intravenously (IV) into the femoral vein of the left leg (n= 6) or to receive
2–8 × 105 CFU BCG ID followed by a second vaccination with 2–8 × 106 CFU
BCG intratracheally (IT; n= 6) 12 weeks later. For the IT boost, 1 ml BCG
was delivered using an endotracheal catheter gauge 8 FG inserted into the
lung to a depth of 15 cm, with the catheter flushed through using 0.5 ml
sterile PBS35.
At 21 weeks post-BCG vaccination, all animals in Studies 1 and 2 were
challenged with 1–4 × 106 CFU and 2–8 × 105 CFU respectively of BCG
Danish strain 1331 (SSI, Copenhagen) by the ID route into the upper arm.
Two weeks after BCG challenge, a skin biopsy of the challenge site was
taken under anaesthesia. The area of skin for biopsy was cleaned with 4%
w/v chlorhexidine preparation (Hibiscrub, Regent Medical Overseas Ltd,
UK) and 1–2ml of local anaesthetic (lignocaine, 10 mg/ml with adrenaline,
5 µg/ml, Xylocaine, AstraZeneca UK) injected subcutaneously in and
around the BCG infection site. After 1–2mins, a 4-mm biopsy was
collected using a disposable biopsy punch (William Needham & Associates,
UK), and the sample was snap frozen. A gauze swab was applied with
pressure to the skin for 0.5–1min and the site cleaned with a moist swab38.
In Study 1, animals were then euthanised under anaesthesia by intra-
cardiac injection of a lethal dose of pentobarbitone sodium (Dolelethal,
Vétoquinol UK Ltd., 140mg/kg). A full necropsy was performed immedi-
ately, gross pathology assessed and the left and right axillary lymph nodes
were collected and snap frozen38. Outcome measures were mycobacterial
burden recovered from skin biopsy (Studies 1 and 2) and lymph nodes
(Study 1), quantified by culture on solid agar and qPCR, the results of which
have been reported elsewhere38.
In Study 3, animals were challenged by endobronchial instillation of 500
CFU of M.tb Erdman strain K01 at 38 weeks after BCG vaccination.
Infectious challenge was performed in two sessions within 2–3 h from
preparing the inoculum from frozen M.tb stock, treating animals from
different groups in a random order. For the endobronchial instillation
procedure, ketamine (5mg kg−1) was supplemented with intramuscular
medetomidine (0.04 mg kg−1) and an analgesic sprayed into the larynx.
The condition of the animals was monitored by daily observation
throughout the study and recorded, with particular attention to behaviour,
stool, appetite and respiratory labour. At the end of the study (50 weeks
post-challenge), or when a humane endpoint was reached to limit possible
discomfort, animals were euthanized by intravenous injection of pento-
barbital under ketamine sedation. Humane endpoint was called by
experienced veterinary staff upon occurrence of adverse indicators
including depression or withdrawn behaviour, abnormal respiration
(dyspnoea) or loss of 20% of peak post-challenge weight. All veterinary
staff members were blinded to the group allocation of individual animals.
Outcome measures were time to humane endpoint (if the fixed endpoint
was not reached), total pathology, lung pathology, extra-thoracic
pathology, lung CFU, C-reactive protein (CRP) and weight change.
In study 4, animals were challenged by exposure to a target dose of 100
CFU of aerosolised M.tb Erdman strain K01 (BEI resources) delivered into
the lungs at 21 weeks after primary vaccination. Mono-dispersed bacteria
in particles of mean diameter 2 µm were generated using a 3-jet Collision
nebuliser (BGI Incorporated, MA, USA) and delivered to the nares of
sedated animals placed in a ‘head-out’ plethysmography chamber (Buxco,
Wilmington, NC, USA) via a veterinary anaesthesia mask (modified to
permit the flow of aerosol over the nose) in conjunction with a modified
Henderson apparatus. This allowed aerosol to be delivered simultaneously
with the measurement of respiration rate and volume. One animal from
each group was exposed in sequence to minimise potential confounders in
order of treatment. Animals were monitored daily for behavioural
abnormalities including depression, aggression, withdrawal, changes in
feeding pattern, altered respiration rate and coughing. Animals were
weighed, had rectal temperature measured and were examined for gross
abnormalities whenever procedures (vaccination, blood sample collection,
mycobacterial challenge or euthanasia) were conducted. Haemoglobin
levels were measured using a HaemaCue haemoglobinometer (Haemacue
Ltd, Dronfield, UK) and erythrocyte sedimentation rates (ESR) were
measured using the Sediplast system (Guest Medical, Edenbridge, UK).
Humane endpoints were determined by experienced primatology staff and
based on a predetermined combination of adverse indicators: depression
or withdrawn behaviour, abnormal respiration (dyspnoea), loss of 20% of
peak post-challenge weight, ESR levels elevated above normal (>20mm),
haemoglobin level below normal limits (<100 g/dl), increased temperature
(>41 °C) and severely altered thoracic radiograph35. Outcome measures
were time of disease control, lung pathology, total pathology, lung lesion
count, lesion:lung ratio, % weight loss, ESR and X-ray score, the results of
which have been reported elsewhere35.
Mycobacterial growth inhibition assay
In-house BCG Pasteur and M.tb H37Rv stocks were grown in Middlebrook
7H9 medium with 10% oleic acid dextrose catalase (OADC) to mid-log
phase, divided into 1ml aliquots and stored at −80 °C until required.
Aliquots were thawed at room temperature immediately prior to
inoculation and diluted to the titres specified in RPMI (containing 2mM
l-glutamine and 25mM HEPES). For harmonisation experiments, frozen
aliquots of a single batch of BCG Pasteur stock (Aeras, Rockville, USA)
grown in Middlebrook 7H9 medium with 10% OADC and 0.05% tyloxapol
were circulated and serially diluted prior to inoculation in a standardised
way between sites. The BCG Pasteur stock prepared by Aeras and tested
for viability and reproducibility is available for future inter-site standardisa-
tion. The whole blood MGIA was performed using fresh whole blood
collected in heparin tubes. For the PBMC MGIA, cryopreserved PBMC were
rapidly thawed in a water bath at 37 °C until a small amount of frozen
material remained. Samples were gradually added to 10ml RPMI
(containing 10% foetal calf serum and 2mM l-glutamine) using a Pasteur
pipette. The cryovial was rinsed using 1 ml of fresh medium and added to
the corresponding tube, which was then centrifuged at 350×g for 7 min.
Supernatants were removed by inversion and cells resuspended at an
approximate concentration of 2–3 × 106 cells per ml of RPMI (containing
10% foetal calf serum and 2mM l-glutamine) and 2 µl/ml of 25 U
benzonase added to each tube. Cells were rested at 37 °C for 2 h with 5%
CO2 before counting.
The direct whole blood MGIA was adapted from the methods of Wallis
et al.57. Duplicate 2ml screw-cap tubes containing 300 μl of fresh whole
blood were mixed with 300 μl RPMI (containing 2mM l-glutamine, 25 mM
HEPES and 10% pooled human AB serum) seeded with ~500 CFU of BCG
Pasteur or M.tb H37Rv. For the direct PBMC ‘in-tube’ assay, 600 µl RPMI
(containing 2mM l-glutamine and 25mM HEPES and 10% pooled human
AB serum) seeded with 1 × 106 PBMC and ~500 CFU BCG Pasteur (unless
otherwise specified) was added to duplicate 2ml screw-cap tubes. The co-
cultures were incubated on a 360° rotator at 37 °C for 96 h, after which time
tubes were microcentrifuged at 15,300×g for 5 mins (whole blood) or
10mins (PBMC) and the supernatant carefully removed by pipetting. Cells
were lysed with the addition of 1 ml (whole blood) or 500 µl (PBMC) sterile
water and the tubes pulse-vortexed at 0, 5 and 10mins. For the PBMC
assay, the 500 µl of lysate was then transferred directly to a BACTEC MGIT
tube supplemented with PANTA antibiotics (polymyxin B, amphotericin B,
nalidixic acid, trimethoprim and azlocillin) and OADC enrichment broth
(Becton Dickinson, UK). For the whole blood assay, lysates were
microcentrifuged at 15,300×g for 10 mins and the supernatant carefully
removed by pipetting. Pellets were resuspended in 500 µl of BACTEC MGIT
medium (supplemented with PANTA and OADC), pulse vortexed and
added to BACTEC MGIT tubes (supplemented with PANTA and OADC).
For the direct PBMC ‘in-plate’ MGIA, 3 × 106 PBMC and ~500 CFU BCG
Pasteur (unless otherwise specified) in a total volume of 480 μl RPMI
(containing 2mM l-glutamine and 25mM HEPES), plus 120 μl autologous
serum matched to animal and time-point (or pooled human AB serum in
studies where this was not available) were added per well of a 48-well
plate (total volume 600 μl per well). Co-cultures were incubated at 37 °C for
96 h and then transferred to 2ml screw-cap tubes and centrifuged at
15,300×g for 10 min. During this time, 500 μl sterile water was added to
each well to lyse adherent monocytes and release intracellular mycobac-
teria. Supernatants were carefully removed from the 2ml screw-cap tubes
by pipetting, and water from the corresponding well added to the
remaining pellet. Tubes were pulse vortexed and the lysate transferred to
BACTEC MGIT tubes supplemented with PANTA antibiotics and OADC
(Becton Dickinson, UK).
At the end of all MGIA protocols described, MGIT tubes were placed on
the BACTEC 960 machine (Becton Dickinson, UK) and incubated at 37 °C
until the detection of positivity by fluorescence. On day 0, duplicate direct-
to-MGIT inoculum control tubes were set up by inoculating supplemented
BACTEC MGIT tubes with the same amount of mycobacteria as the
samples. The time to positivity (TTP) read-out was converted to log10 CFU
using stock standard curves of TTP against inoculum volume and CFU.
Results are presented as ‘normalised mycobacterial growth’ which is equal
to (log10 CFU of sample – log10 CFU of inoculum control) to correct
for variation in inoculum between mycobacterial stocks, batches and
aliquots. ‘Vaccine response’ following BCG vaccination was calculated as
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(post-vaccination normalised growth – baseline normalised growth), and is
presented as Δlog10 CFU.
Statistical analysis
Statistical analysis was performed using GraphPad Prism v.7 and IBM SPSS
v.25. Normality of data was determined using a Shapiro-Wilk test. For
parametric data with multiple groups, a one-way ANOVA or repeated-
measures ANOVA (for time-course data) was conducted followed by a
Tukey’s post-test (comparison of all groups) or Dunnett’s/Sidak’s multiple
comparisons test (comparison of preselected pairs of groups ie. post-
vaccination timepoints vs. baseline). For comparisons between two groups of
normally-distributed data, a two-sided t-test or paired t-test was used. For
comparisons between two groups of non-parametric data or small sample
sizes, a two-sided Mann Whitney or Wilcoxon matched-pairs signed rank test
was conducted. Effect sizes are estimated as the difference between the
means (MD) of the two groups. A two-tailed Spearman’s rank correlation was
used to determine associations between two measures. For determination of
intra-assay repeatability, intermediate (inter-assay) precision and inter-site
reproducibility, the coefficients of variation (CV) (standard deviation/mean ×
100) and intra-class correlation coefficients (ICC) (two-way mixed model,
consistency agreement, single measures) were calculated using raw time-to-
positivity (TTP) values. ICC categories for interpreting kappa values were
taken from the guidelines of Landis and Koch58. Following confirmation of
normality in the distribution of differences between paired measurements,
the Bland-Altman method was used to analyse the intermediate precision
and inter-site reproducibility of normalised mycobacterial growth values59.
95% confidence intervals for the Bland-Altman limits of agreement were
calculated using the methods described by Carkeet60.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
The datasets generated and analysed during the current study are available from the
corresponding author on reasonable request.
Received: 23 July 2020; Accepted: 23 November 2020;
REFERENCES
1. WHO. World Health Organisation Global tuberculosis report 2020. (2020).
2. Fletcher, H. A. & Dockrell, H. M. Human biomarkers: can they help us to develop a
new tuberculosis vaccine? Future Microbiol. 11, 781–787 (2016).
3. Flores-Valdez, M. A. New potential biomarkers to assess efficacy of protection
afforded by vaccine candidates against tuberculosis. Clin. Microbiol. Infect. 25,
656–658 (2019).
4. Sable, S. B., Posey, J. E. & Scriba, T. J. Tuberculosis vaccine development: progress
in clinical evaluation. Clin. Microbiol. Rev. https://doi.org/10.1128/cmr.00100-19
(2019).
5. Gross, D. & Tolba, R. H. Ethics in animal-based research. Eur. Surg. Res. 55, 43–57
(2015).
6. Directive 2010/63/EU of the European Parliament and of the Council of 22
September 2010 on the protection of animals used for scientific purposes. Off. J.
Eur. Union 28, 82–128 (2010).
7. McShane, H. & Williams, A. A review of preclinical animal models utilised for TB
vaccine evaluation in the context of recent human efficacy data. Tuberculosis 94,
105–110 (2014).
8. Laddy, D. J. et al. Toward tuberculosis vaccine development: recommendations
for nonhuman primate study design. Infect. Immun. https://doi.org/10.1128/
iai.00776-17 (2018).
9. Burden, N., Chapman, K., Sewell, F. & Robinson, V. Pioneering better science
through the 3Rs: an introduction to the national centre for the replacement,
refinement, and reduction of animals in research (NC3Rs). J. Am. Assoc. Lab. Anim.
Sci. 54, 198–208 (2015).
10. Tanner, R., O’Shea, M. K., Fletcher, H. A. & McShane, H. In vitro mycobacterial
growth inhibition assays: a tool for the assessment of protective immunity and
evaluation of tuberculosis vaccine efficacy. Vaccine https://doi.org/10.1016/j.
vaccine.2016.07.058 (2016).
11. Kampmann, B. et al. Evaluation of human antimycobacterial immunity using
recombinant reporter mycobacteria. J. Infect. Dis. 182, 895–901 (2000).
12. Cheon, S. H. et al. Bactericidal activity in whole blood as a potential surrogate
marker of immunity after vaccination against tuberculosis. Clin. Diagn. Lab.
Immunol. 9, 901–907 (2002).
13. Silver, R. F., Li, Q., Boom, W. H. & Ellner, J. J. Lymphocyte-dependent inhibition of
growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes:
requirement for CD4+ T cells in purified protein derivative-positive, but not in
purified protein derivative-negative subjects. J. Immunol. 160, 2408–2417 (1998).
14. Worku, S. & Hoft, D. F. In vitro measurement of protective mycobacterial
immunity: antigen-specific expansion of T cells capable of inhibiting intracellular
growth of bacille Calmette-Guérin. Clin. Infect. Dis. 30, S257–S261 (2000).
15. Cheng, S. H. et al. Demonstration of increased anti-mycobacterial activity in
peripheral blood monocytes after BCG vaccination in British school children. Clin.
Exp. Immunol. 74, 20–25 (1988).
16. Hoft, D. F. et al. Investigation of the relationships between immune-mediated
inhibition of mycobacterial growth and other potential surrogate markers of
protective Mycobacterium tuberculosis immunity. J. Infect. Dis. 186, 1448–1457
(2002).
17. Cowley, S. C. & Elkins, K. L. CD4+ T cells mediate IFN-gamma-independent control
of Mycobacterium tuberculosis infection both in vitro and in vivo. J. Immunol.
171, 4689–4699 (2003).
18. Kolibab, K. et al. A practical in vitro growth inhibition assay for the evaluation of
TB vaccines. Vaccine 28, 317–322 (2009).
19. Sada-Ovalle, I., Chiba, A., Gonzales, A., Brenner, M. B. & Behar, S. M. Innate
invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages,
produce interferon-gamma, and kill intracellular bacteria. PLoS Pathog. 4,
e1000239 (2008).
20. Marsay, L. et al. Mycobacterial growth inhibition in murine splenocytes as a
surrogate for protection against Mycobacterium tuberculosis (M. tb). Tuberculosis
93, 551–557 (2013).
21. Zelmer, A. et al. A new tool for tuberculosis vaccine screening: Ex vivo Myco-
bacterial Growth Inhibition Assay indicates BCG-mediated protection in a murine
model of tuberculosis. BMC Infect. Dis. 16, 412 (2016).
22. Painter, H. et al. Adaption of the ex vivo mycobacterial growth inhibition assay for
use with murine lung cells. Sci. Rep. 10, 3311 (2020).
23. Parra, M. et al. Development of a murine mycobacterial growth inhibition assay
for evaluating vaccines against Mycobacterium tuberculosis. Clin. Vaccine
Immunol. 16, 1025–1032 (2009).
24. Carpenter, E., Fray, L. & Gormley, E. Cellular responses and Mycobacterium bovis
BCG growth inhibition by bovine lymphocytes. Immunol. Cell Biol. 75, 554–560
(1997).
25. Denis, M., Wedlock, D. N. & Buddle, B. M. Ability of T cell subsets and their soluble
mediators to modulate the replication of Mycobacterium bovis in bovine mac-
rophages. Cell Immunol. 232, 1–8 (2004).
26. Pepponi, I. et al. A mycobacterial growth inhibition assay (MGIA) for bovine TB
vaccine development. Tuberculosis 106, 118–122 (2017).
27. Joosten, S. A. et al. Mycobacterial growth inhibition is associated with trained
innate immunity. J. Clin. Invest. 128, 1837–1851 (2018).
28. O’Shea, M. K. et al. Immunological correlates of mycobacterial growth inhibition
describe a spectrum of tuberculosis infection. Sci. Rep. 8, 14480 (2018).
29. Tanner, R. et al. The influence of haemoglobin and iron on in vitro mycobacterial
growth inhibition assays. Sci. Rep. 7, 43478 (2017).
30. Dijkman, K. et al. Disparate tuberculosis disease development in macaque species
is associated with innate immunity. Front. Immunol. 10, 2479–2479 (2019).
31. Verreck, F. A. et al. MVA.85A boosting of BCG and an attenuated, phoP deficient
M. tuberculosis vaccine both show protective efficacy against tuberculosis in
rhesus macaques. PLoS ONE 4, e5264 (2009).
32. Sharpe, S. A. et al. Establishment of an aerosol challenge model of tuberculosis in
rhesus macaques and an evaluation of endpoints for vaccine testing. Clin. Vaccine
Immunol. 17, 1170–1182 (2010).
33. Dijkman, K. et al. Prevention of tuberculosis infection and disease by local BCG in
repeatedly exposed rhesus macaques. Nat. Med. 25, 255–262 (2019).
34. Sharpe, S. et al. Ultra low dose aerosol challenge with Mycobacterium tubercu-
losis leads to divergent outcomes in rhesus and cynomolgus macaques. Tuber-
culosis 96, 1–12 (2016).
35. Sharpe, S. et al. Alternative BCG delivery strategies improve protection against
Mycobacterium tuberculosis in non-human primates: protection associated with
mycobacterial antigen-specific CD4 effector memory T-cell populations. Tuber-
culosis 101, 174–190 (2016).
36. Verreck, F. A. W. et al. Variable BCG efficacy in rhesus populations: Pulmonary BCG
provides protection where standard intra-dermal vaccination fails. Tuberculosis
104, 46–57 (2017).
37. Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic
review of randomized controlled trials. Clin. Infect. Dis. 58, 470–480 (2014).
R. Tanner et al.
10
npj Vaccines (2021)     3 Published in partnership with the Sealy Institute for Vaccine Sciences
38. Harris, S. A. et al. Development of a non-human primate BCG infection model for
the evaluation of candidate tuberculosis vaccines. Tuberculosis 108, 99–105
https://doi.org/10.1016/j.tube.2017.11.006 (2018).
39. Fletcher, H. A. et al. Inhibition of mycobacterial growth in vitro following primary
but not secondary vaccination with Mycobacterium bovis BCG. Clin. Vaccine
Immunol. 20, 1683–1689 (2013).
40. Brennan, M. J. et al. The cross-species Mycobacterial Growth Inhibition Assay
(MGIA) Project, 2010-2014. Clin. Vaccine Immunol. https://doi.org/10.1128/
CVI.00142-17 (2017).
41. Tanner, R. & McShane, H. Replacing, reducing and refining the use of animals in
tuberculosis vaccine research. ALTEX https://doi.org/10.14573/altex.1607281
(2016).
42. Yang, A. L. et al. A simplified mycobacterial growth inhibition assay (MGIA) using
direct infection of mouse splenocytes and the MGIT system. J. Microbiol. Methods
131, 7–9 (2016).
43. Tanner, R. et al. Optimisation, harmonisation and standardisation of the direct
mycobacterial growth inhibition assay using cryopreserved human peripheral
blood mononuclear cells. J. Immunol. Methods https://doi.org/10.1016/j.
jim.2019.01.006 (2019).
44. Larsen, M. H. et al. Efficacy and safety of live attenuated persistent and rapidly
cleared Mycobacterium tuberculosis vaccine candidates in non-human primates.
Vaccine 27, 4709–4717 (2009).
45. Lin, P. L. et al. The multistage vaccine H56 boosts the effects of BCG to protect
cynomolgus macaques against active tuberculosis and reactivation of
latent Mycobacterium tuberculosis infection. J. Clin. Investig. 122, 303–314
(2012).
46. White, A. D. et al. Evaluation of the safety and immunogenicity of a candidate
tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
Clin. Vaccine Immunol. 20, 663–672 (2013).
47. Haberthur, K., Engelman, F., Barron, A. & Messaoudi, I. Immune senescence in
aged nonhuman primates. Exp. Gerontol. 45, 655–661 (2010).
48. Smith, S. G. et al. Assay optimisation and technology transfer for multi-site
immuno-monitoring in vaccine trials. PLoS ONE 12, e0184391 (2017).
49. Bartlett, J. W. & Frost, C. Reliability, repeatability and reproducibility: analysis of
measurement errors in continuous variables. Ultrasound Obstet. Gynecol. 31,
466–475 (2008).
50. Tuomela, M., Stanescu, I. & Krohn, K. Validation overview of bio-analytical
methods. Gene Ther. 12, S131–S138 (2005).
51. Darrah, P. A. et al. Prevention of tuberculosis in macaques after intravenous BCG
immunization. Nature 577, 95–102 (2020).
52. Langermans, J. A. et al. Divergent effect of bacillus Calmette-Guérin (BCG) vac-
cination on Mycobacterium tuberculosis infection in highly related macaque
species: implications for primate models in tuberculosis vaccine research. Proc.
Natl Acad. Sci. USA 98, 11497–11502 (2001).
53. Naranbhai, V. et al. Distinct transcriptional and anti-mycobacterial profiles of
peripheral blood monocytes dependent on the ratio of monocytes: lymphocytes.
EBioMedicine 2, 1619–1626 (2015).
54. Smith, S. G., Zelmer, A., Blitz, R., Fletcher, H. A. & Dockrell, H. M. Polyfunctional
CD4 T-cells correlate with in vitro mycobacterial growth inhibition
following Mycobacterium bovis BCG-vaccination of infants. Vaccine 34,
5298–5305 (2016).
55. Tanner, R. et al. Tools for assessing the protective efficacy of TB vaccines in
humans: in vitro mycobacterial growth inhibition predicts outcome of in vivo
mycobacterial infection. Front. Immunol. 10, 2983 (2020).
56. Peña, J. C. & Ho, W.-Z. Monkey models of tuberculosis: lessons learned. Infect.
Immun. 83, 852 (2015).
57. Wallis, R. S. et al. A whole blood bactericidal assay for tuberculosis. J. Infect. Dis.
183, 1300–1303 (2001).
58. Landis, J. R. & Koch, G. G. The measurement of observer agreement for catego-
rical data. Biometrics 33, 159–174 (1977).
59. Altman, D. G. & Bland, J. M. Measurement in medicine: the analysis of method
comparison studies. J. R. Stat. Soc. Ser. D 32, 307–317 (1983).
60. Carkeet, A. Exact parametric confidence intervals for bland-altman limits of
agreement. Opt. Vis. Sci. 92, e71-80(2015).
ACKNOWLEDGEMENTS
This work was funded by a grant awarded to RT by the National Centre for the
Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (grant
number NC/R000905/1); and in part by a studentship awarded to RT by the
Universities Federation for Animal Welfare (UFAW). Aspects of this work were
conducted as part of the European Research Infrastructures for Poverty Related
Diseases (EURIPRED), an EC seventh framework program (grant number 312661).
HMcS is a Wellcome Trust Investigator (grant number WT 206331/Z/17/Z). We
would like to thank Aeras for supporting the early MGIA development work and
NHP Study 3, and for providing and distributing a standardised BCG Pasteur stock.
We are grateful to Krista van Meijgaarden and Tom Ottenhoff (Leiden University
Medical Centre) and to Marcus Morgan (Oxford University Hospitals NHS Trust) for
use of their BD BACTEC MGIT machines for parts of this project. We would also like
to thank Michael Andrews (University of California, Los Angeles) for advice on
some of the statistical aspects.
AUTHOR CONTRIBUTIONS
R.T., H.A.F., F.A.W.V., S.A.S. and H.M. conceived and designed the work; R.T., A.W., C.B.,
C.C.S., M.K.O., D.W., E.H., J.B., S.A.H., C.S., R.W. and I.S. contributed to the acquisition of
data; R.T., H.A.F,. F.A.W.V., S.A.S. and H.M. contributed to the interpretation of data. R.T.
wrote the paper and all authors provided critical analysis and approved the
submitted version.
COMPETING INTERESTS
The authors declare no competing interests.
ADDITIONAL INFORMATION
Supplementary information is available for this paper at https://doi.org/10.1038/
s41541-020-00263-7.
Correspondence and requests for materials should be addressed to R.T.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
R. Tanner et al.
11
Published in partnership with the Sealy Institute for Vaccine Sciences npj Vaccines (2021)     3 
